Harpoon Therapeutics to Present Interim Tolerability and Res

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Madrid , Spain , Noura Choudhury , Luke Walker , Nasdaq , Harpoon Therapeutics Inc , Exchange Commission , European Society Of Medical Oncology Congress , Harpoon Therapeutics , European Society , Medical Oncology Congress , Activating Construct , Chief Medical Officer , Interim Results , T Cell Engager , Small Cell Lung Cancer , Neuroendocrine Neoplasms , Private Securities Litigation Reform Act , Harpoon Therapeutic ,